A comparison of the effects of the dopamine partial agonists aripiprazole and (-)-3-PPP with quinpirole on stimulated dopamine release in the rat striatum: Studies using fast cyclic voltammetry in vitro

European Journal of Pharmacology

Volumn 686, Issue 1-3, 2012, Pages 60-65

  O'Connor, John J ^a,b   Lowry, John P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

3 PPP; Aripiprazole; Autoreceptor; Dopamine release; Partial antagonist; Quinpirole; Voltammetry

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; PRECLAMOL; QUINPIROLE;

ANIMAL TISSUE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; CYCLIC POTENTIOMETRY; DOPAMINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; ELECTROENCEPHALOGRAM; ENZYME INHIBITION; FAST CYCLIC POTENTIOMETRY; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DRUG PARTIAL AGONISM; MALE; PIPERAZINES; PIPERIDINES; QUINOLONES; QUINPIROLE; RATS; RATS, WISTAR;

EID: 84861640253     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.04.046     Document Type: Article

References (31)

1. S. Arbilla, and S.Z. Langer Differential effects of the stereoisomers of 3PPP on dopaminergic and cholinergic neurotransmission in superfused slices of the corpus striatum Naunyn Schmiedebergs Arch. Pharmacol. 327 1984 6 13
2. M. Armstrong-James, and J. Millar Carbon fibre microelectrodes J. Neurosci. Methods 1 1979 279 287
3. A. Bortolozzi, L. Díaz-Mataix, M. Toth, P. Celada, and F. Artigas In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain Psychopharmacology (Berl.) 191 2007 745 758
4. D.R. Bull, and M.J. Sheehan Presynaptic regulation of electrically evoked dopamine overflow in nucleus accumbens: a pharmacological study using fast cyclic voltammetry in vitro Naunyn Schmiedebergs Arch. Pharmacol. 343 1991 260 265
5. D. Clark, S. Hjorth, and A. Carlsson (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis Eur. J. Pharmacol. 106 1984 185 189
6. C. Cosi, E. Carilla-Durand, M.B. Assié, A.M. Ormiere, M. Maraval, N. Leduc, and A. Newman-Tancredi Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release Eur. J. Pharmacol. 535 2006 135 144
7. P. Hertel Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action Synapse 60 2006 543 552
8. S. Jordan, V. Koprivica, R. Chen, K. Tottori, T. Kikuchi, and C.A. Altar The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor Eur. J. Pharmacol. 441 2002 137 140
9. B. Koener, S. Goursaud, M. Van De Stadt, A.G. Calas, A.P. Jeanjean, J.M. Maloteaux, and E. Hermans Pharmacological blockade of dopamine D receptors by aripiprazole is not associated with striatal sensitization Naunyn Schmiedebergs Arch. Pharmacol. 383 2011 65 77
10. Z.L. Kruk, and J.J. O'Connor Fast electrochemical studies in isolated tissues Trends Pharmacol. Sci. 16 1995 145 149
11. C.P. Lawler, C. Prioleau, M.M. Lewis, C. Mak, D. Jiang, J.A. Schetz, A.M. Gonzalez, D.R. Sibley, and R.B. Mailman Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes Neuropsychopharmacology 20 1999 612 627
12. N. Limberger, S.J. Trout, Z.L. Kruk, and K. Starke Real time measurement of endogenous dopamine release during short trains of pulses in slices of rat neostriatum and nucleus accumbens: role of autoinhibition Naunyn Schmiedebergs Arch. Pharmacol. 344 1991 623 629
13. R. Markstein, and D. Lahaye In vitro effect of the racemic mixture and the (-) enantiomer of N-n-propyl-3-(3-hydroxyphenyl)-piperidine (3-PPP) on postsynaptic dopamine receptors and on a presynaptic dopamine autoreceptor J. Neural. Transm. 58 1983 43 53
14. J. Millar, and T.G. Barnett Basic instrumentation for fast cyclic voltammetry J. Neurosci. Methods 25 1988 91 95
15. A.H. Mulder, R. Draper, P. Sminia, A.N. Schoffelmeer, and J.C. Stoof Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro Eur. J. Pharmacol. 107 1985 291 297
16. D. Muralikrishnan, M. Ebadi, and H.M. Brown-Borg Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity Neurochem. Res. 29 2004 379 384
17. C. O'Neill, and J.J. O'Connor An investigation into the influence of NMDA and GABA on the modulation of electrically stimulated dopamine release by adenosine in the rat striatum: studies using fast cyclic voltammetry Sensors 8 2008 5229 5237
18. J.J. O'Connor, and Z.L. Kruk Fast cyclic voltammetry can be used to measure stimulated endogenous 5-hydroxytryptamine release in untreated rat brain slices J. Neurosci. Methods 38 1991 25 33
19. J.J. O'Connor, and Z.L. Kruk Pharmacological characteristics of 5-hydroxytryptamine autoreceptors in rat brain slices incorporating the dorsal raphe or the suprachiasmatic nucleus Br. J. Pharmacol. 106 1992 524 532
20. C. O'Neill, A. Evers-Donnelly, D. Nicholson, K.M. O'Boyle, and J.J. O'Connor D2 receptor-mediated inhibition of dopamine release in the rat striatum in vitro is modulated by CB1 receptors: studies using fast cyclic voltammetry J. Neurochem. 108 2009 545 551
21. H. Oshibuchi, K. Inada, H. Sugawara, and J. Ishigooka Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats Eur. J. Pharmacol. 615 2009 83 90
22. P. Palij, D.R. Bull, M.J. Sheehan, J. Millar, J. Stamford, Z.L. Kruk, and P.P. Humphrey Presynaptic regulation of dopamine release in corpus striatum monitored in vitro in real time by fast cyclic voltammetry Brain Res. 509 1990 172 174
23. J.F. Plantjé, A.H. Mulder, and J.C. Stoof 3-PPP antagonizes the in vitro effects of D-1 and D-2 dopamine receptor agonists in rat neostriatum Eur. J. Pharmacol. 91 1983 317 320
24. J.F. Plantjé, H.A. Hansen, F.J. Daus, and J.C. Stoof The effects of SCH 23390, YM 09151-2, (+)- and (-)-3-PPP and some classical neuroleptics on D-1 and D-2 receptors in rat neostriatum in vitro Eur. J. Pharmacol. 105 1984 73 83
25. A. Spiros, R. Carr, and H. Geerts Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse Neuropsychiatr. Dis. Treat. 6 2010 589 603
26. J.A. Stamford Fast cyclic voltammetry: measuring transmitter release in 'real time' J. Neurosci. Methods 34 1990 67 72
27. J.A. Stamford, Z.L. Kruk, and J. Millar Differential effects of dopamine agonists upon stimulated limbic and striatal dopamine release: in vivo voltammetric data Br. J. Pharmacol. 102 1991 45 50
28. Y. Tadori, R.A. Forbes, R.D. McQuade, and T. Kikuchi Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors Eur. J. Pharmacol. 597 2008 27 33
29. S.J. Trout, and Z.L. Kruk Differences in evoked dopamine efflux in rat caudate putamen, nucleus accumbens and tuberculum olfactorium in the absence of uptake inhibition: influence of autoreceptors Br. J. Pharmacol. 106 1992 452 458
30. J.D. Urban, G.A. Vargas, M. von Zastrow, and R.B. Mailman Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways Neuropsychopharmacology 32 2007 67 77
31. A. Zocchi, D. Fabbri, and C.A. Heidbreder Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex Neurosci. Lett. 387 2005 157 161